GBP2 Inhibitors
The class of GBP2 inhibitors encompasses a diverse range of chemicals that offers strategies for modulating GBP2 activity. These compounds target various cellular pathways and processes, including Rho GTPase, MAPK/ERK, PI3K/Akt, and stress response signaling, influencing cellular dynamics and stress-related responses. NSC 23766, a specific inhibitor of Rac1, may indirectly inhibit GBP2 by affecting cytoskeletal dynamics and cell migration. GW 5074, a c-Raf inhibitor, modulate GBP2 indirectly by disrupting the MAPK/ERK signaling pathway, impacting cell proliferation and survival. SB 203580, a p38 MAPK inhibitor, may influence GBP2 indirectly by affecting stress response pathways. LY294002 and Wortmannin, both PI3K inhibitors, offer avenues for indirect GBP2 inhibition by disrupting the PI3K/Akt signaling axis, crucial for cell survival and growth. U0126 and PD 98059, MEK inhibitors, may act as indirect inhibitors of GBP2 by modulating the MAPK/ERK pathway, which plays a role in cellular responses to various stimuli. SP600125, a JNK inhibitor, modulate GBP2 by influencing stress-related signaling events.
Cisplatin, a DNA-damaging agent, may impact GBP2 indirectly by affecting cellular stress and DNA repair mechanisms. SB 431542, an inhibitor of the TGF-β type I receptor, offers a route for indirect GBP2 modulation by disrupting TGF-β signaling, which regulates various cellular processes. TAK-715, another p38 MAPK inhibitor, may influence GBP2 indirectly by affecting stress response pathways. LY303511, a structural analog of LY294002, provides an additional option for modulating GBP2 indirectly through PI3K/Akt signaling disruption. This diverse class of GBP2 inhibitors provides valuable tools for investigating the dynamic interplay between cellular processes and GBP2 activity, contributing to a deeper understanding of this protein's role in cellular function.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW 5074 is a c-Raf inhibitor that can impact the MAPK/ERK signaling pathway. By inhibiting c-Raf, it disrupts the activation of the downstream MEK-ERK pathway, which plays a role in cell proliferation and survival. GBP2 has been associated with cellular responses to various stimuli, and its modulation could be influenced by the MAPK/ERK pathway. GW 5074 may act as an indirect inhibitor of GBP2 by targeting the signaling cascade associated with its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK, a kinase involved in stress response pathways. Inhibition of p38 MAPK can affect cellular processes such as inflammation and apoptosis. GBP2 has been implicated in interferon-induced responses, and p38 MAPK inhibition by SB 203580 may modulate GBP2 indirectly by influencing the cellular stress response. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor that disrupts the PI3K/Akt signaling pathway. This pathway is crucial for cell survival and growth. GBP2 has been linked to cellular proliferation and survival, and the inhibition of PI3K by LY294002 can potentially influence GBP2 activity indirectly by affecting the PI3K/Akt signaling axis. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK (c-Jun N-terminal kinase) inhibitor that affects the JNK signaling pathway involved in stress response and apoptosis. GBP2 has been linked to cellular stress responses, and the inhibition of JNK by SP600125 may modulate GBP2 indirectly by influencing stress-related signaling events. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor that disrupts the PI3K/Akt signaling pathway. This pathway is crucial for cell survival and growth. GBP2 has been linked to cellular proliferation and survival, and the inhibition of PI3K by Wortmannin can potentially influence GBP2 activity indirectly by affecting the PI3K/Akt signaling axis. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin is a DNA-damaging agent used in chemotherapy. While its primary mode of action is through DNA binding, it can also affect cellular processes beyond DNA damage. GBP2 has been implicated in cellular responses to stress and DNA damage. Cisplatin's impact on cellular stress and DNA repair mechanisms may lead to indirect modulation of GBP2 activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB 431542 is an inhibitor of the TGF-β type I receptor (ALK5). It disrupts the TGF-β signaling pathway, which regulates various cellular processes, including cell growth and differentiation. GBP2 has been associated with interferon-induced responses, and the inhibition of TGF-β signaling by SB 431542 may modulate GBP2 indirectly by influencing cellular responses to various stimuli. | ||||||
TAK 715 | 303162-79-0 | sc-362799 sc-362799A | 10 mg 50 mg | $185.00 $781.00 | ||
TAK-715 is an inhibitor of p38 MAPK, a kinase involved in stress response pathways. Inhibition of p38 MAPK can affect cellular processes such as inflammation and apoptosis. GBP2 has been implicated in interferon-induced responses, and p38 MAPK inhibition by TAK-715 may modulate GBP2 indirectly by influencing the cellular stress response. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $66.00 $273.00 | 3 | |
LY303511 is a structural analog of LY294002 and acts as a phosphoinositide 3-kinase (PI3K) inhibitor. It disrupts the PI3K/Akt signaling pathway, crucial for cell survival and growth. GBP2 has been linked to cellular proliferation and survival, and the inhibition of PI3K by LY303511 can potentially influence GBP2 activity indirectly by affecting the PI3K/Akt signaling axis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK1 inhibitor that impacts the MAPK/ERK signaling pathway. It disrupts the activation of ERK, a downstream target of MEK, affecting cellular processes such as proliferation and differentiation. GBP2 has been associated with interferon responses, and PD 98059 may act as an indirect inhibitor of GBP2 by modulating the MAPK/ERK pathway, which plays a role in cellular responses to various stimuli. | ||||||